Okhuijsen-Pfeifer, C. http://orcid.org/0000-0002-9649-3879
van der Horst, M. Z. http://orcid.org/0000-0001-5090-4137
Bousman, C. A. http://orcid.org/0000-0001-6303-8696
Lin, B.
van Eijk, K. R.
Ripke, S.
Ayhan, Y.
Babaoglu, M. O.
Bak, M.
Alink, W.
van Beek, H.
Beld, E.
Bouhuis, A.
Edlinger, M.
Erdogan, I. M. http://orcid.org/0000-0003-3319-4924
Ertuğrul, A.
Yoca, G.
Everall, I. P.
Görlitz, T.
van Amelsvoort, T.
Bartels-Velthuis, A. A.
Bruggeman, R.
Cahn, W.
Guloksuz, S.
de Haan, L.
Kahn, R. S.
Schirmbeck, F.
Simons, C. J. P.
van Os, J.
Alizadeh, B. Z.
Luykx, J. J.
Rutten, B. P. F.
van Winkel, R.
Grootens, K. P.
Gutwinski, S.
Hallikainen, T.
Jeger-Land, E.
de Koning, M.
Lähteenvuo, M. http://orcid.org/0000-0002-7244-145X
Legge, S. E. http://orcid.org/0000-0001-6617-0289
Leucht, S.
Morgenroth, C.
Müderrisoğlu, A.
Narang, A.
Pantelis, C. http://orcid.org/0000-0002-9565-0238
Pardiñas, A. F. http://orcid.org/0000-0001-6845-7590
Oviedo-Salcedo, T.
Schneider-Thoma, J.
Schreiter, S.
Repo-Tiihonen, E.
Tuppurainen, H.
Veereschild, M.
Veerman, S.
de Vos, M.
Wagner, E. http://orcid.org/0000-0002-7147-6167
Cohen, D.
Bogers, J. P. A. M. http://orcid.org/0000-0001-7273-0027
Walters, J. T. R.
Yağcıoğlu, A. E. Anil
Tiihonen, J. http://orcid.org/0000-0002-0400-6798
Hasan, A.
Luykx, J. J. http://orcid.org/0000-0002-6439-2774
,
Funding for this research was provided by:
Alberta Innovates (G2018000868)
Article History
Received: 27 September 2021
Revised: 24 February 2022
Accepted: 7 March 2022
First Online: 7 April 2022
Competing interests
: Dr. Bousman reports he has received in-kind testing kits from Myriad Neuroscience, CNSDose, Genomind, and AB-Biotics for research purposes but has not received payments or received any equity, stocks, or options in these companies or any other pharmacogenetic companies. Dr. Lähteenvuo reports being a shareholder and board member at Genomi Solutions Ltd and Nursie Health Ltd; receiving research grants or awards from the Finnish Medical Foundation and Emil Aaltonen Foundation; receiving travel grants or speakers’ honoraria from Sunovion Ltd, Janssen-Cilag, Otsuka Pharmaceutical Ltd, Lundbeck Ltd, Orion Pharma ltd; and working as a coordinator for a research project funded by the Stanley Foundation. Dr. A.E. Anil Yağcıoğlu has recently received travel grants or speakers’ honoraria from Janssen, Otsuka; is a member of the advisory board for Janssen, Otsuka; is currently participating in an international clinical trial funded by Janssen. Dr. Tiihonen reports personal fees from the Finnish Medicines Agency (Fimea), European Medicines Agency (EMA), Eli Lilly, Janssen, Lundbeck, and Otsuka; is a member of the advisory board for Lundbeck; and has participated in research projects funded by grants from Eli Lilly and Janssen to his employing institution. All other authors have declared that there are no conflicts of interest in relation to the subject of this study.